Results of Operations and Financial Condition. This Amendment No. 1 includes (i) the financial statements of Pre-Merger Yarrow as of and for the three and six months ended June 30, 2026, (ii) the financial statements of Pre-Merger Yarrow as of December 31, 2025 and October 3, 2025, and for the period from October 3, 2025 (inception) to December 31, 2025, which have been recast to give retroactive effect to the Exchange Ratio, (iii) Pre-Merger Yarrow’s Management’s Discussion and Analysis of F…

of this Current Report on Form 8-K is incorporated herein by reference. Amended and Restated Bylaws In connection with the Closing, on July 27, 2026, the Board adopted the Amended and Restated Bylaws of the Company (the “Amended and Restated Bylaws”), which amended and restated the Company’s bylaws as in effect immediately prior to the Closing in their entirety. The Amended and Restated Bylaws, among other things: · update various provisions regarding the order and conduct of meetings of stoc…

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Results of Operations and Financial Condition. Pre-Merger Yarrow’s Management’s Discussion and Analysis of Financial Condition and Results of Operations as of March 31, 2026 and for the period from October 3, 2025 (inception) to March 31, 2026 is included in the Proxy Statement/Prospectus beginning on page 307 and is incorporated herein by reference.

Entry into a Material Definitive Agreement. Indemnification Agreements On July 27, 2026, the Company entered into indemnification agreements (collectively, the “Indemnification Agreements”) with each of its directors and executive officers (collectively, the “Indemnitees”), which replaced and superseded any previous indemnification agreements between the Company and each such individual. The Indemnification Agreements provide for certain indemnification and advancement of expenses by the Comp…

of this Current Report on Form 8-K is incorporated herein by reference. VYNE held the Special Meeting on July 16, 2026 to present the proposals included in the Proxy Statement/Prospectus. At the Special Meeting, the VYNE stockholders approved, among other matters, amendments to the Amended and Restated Certificate of Incorporation of the Company to (i) increase the number of authorized shares of Company Common Stock from 150,000,000 shares to 300,000,000 shares (the “Authorized Share Increase…

Director, President, Chief Executive Officer, Chief Scientific Officer, Chief Legal Officer and General Counsel — David Domzalski, Iain Stuart, Ph.D., Mutya Harsch: All directors and certain officers resigned due to a merger, resulting in their termination without cause.

Changes in Control of Registrant. To the extent required by this Item, the information included under the heading “ Introductory Note ” and in

Other Events. At the special meeting in lieu of the annual meeting of VYNE stockholders on July 16, 2026 (the “Special Meeting”), VYNE’s stockholders approved a proposal to amend the amended and restated certificate of incorporation of VYNE (the “VYNE Charter”) to effect a reverse stock split of issued and outstanding common stock of VYNE, par value $0.0001 per share (the “VYNE Common Stock”), at a ratio determined by the VYNE board of directors and agreed to by Yarrow, of one new share of VY…

Other Events. As previously disclosed, on December 17, 2025, the Company entered into an Agreement and Plan of Merger and Reorganization (as amended, the “Merger Agreement”) with Yarrow Bioscience, Inc., a Delaware corporation (“Yarrow”), and Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub w…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in a Current Report on Form 8-K filed by VYNE Therapeutics Inc. (the “Company”) on September 12, 2025, the Company received a notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing b…

shall have the meanings ascribed to such terms in the Merger Agreement. The Amendment provides that VYNE may provide certain pre-funded warrants (the “Pre-Funded Warrants”), substantially in the form attached to the Amendment as Exhibit E thereto, to holders of Yarrow capital stock in the event that they would receive, pursuant to the Exchange Ratio, a number of shares of the common stock, $0.0001 par value per share, of VYNE (“VYNE Common Stock”), that (when aggregated with all Securities th…

Entry into a Material Definitive Agreement. Merger Agreement On December 17, 2025, VYNE Therapeutics Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Yarrow Bioscience, Inc., a Delaware corporation (“Yarrow”), and Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), pursuant to which, among other matters, and subject to the satisfaction or waiver of…

Regulation FD Disclosure. On December 17, 2025, the Company and Yarrow issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. The Company and Yarrow plan to hold a joint conference call on December 17, 2025 at 8:30 AM Eastern Ti…

Changes in Control of Registrant. To the extent required by this Item, the information included in

The filing appears to be a placeholder or incomplete, and does not specify any actual movement.

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 11, 2025, VYNE Therapeutics Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per…

Director — Christine Borowski, Ph.D., Anthony Bruno: Both directors resigned from their positions on the board and committees.

of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition. The information set forth below in the second paragraph of

of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Approval of an amendment to the 2023 Equity Incentive Plan.